Point mutation, deep deletion, amplification, shallow deletion, and copy number gain of m6A regulatory genes in hematological malignancies. (a) Percentage of leukemia samples with alteration to the genes encoding m6A regulators based on the Cancer Genome Atlas Research Network (TCGA) data. (b) Frequency of copy number gain or loss of the m6A regulatory genes in the TCGA AML samples. AML, Acute Myeloid Leukemia; MM, Multiple Myeloma; ALL, Acute Lymphoblastic Leukemia; CLL, Chronic Lymphocytic Leukemia. (PDF 361 kb
Figure S6. WT1 mutations in the AML but not MDS samples of the patient. (DOCX 1483 kb
Figure S1. Mutation patterns of the identified 32 MDGs across 20 TCGA tumor types. Each row represen...
Figure S1. ROC curve analysis using H19 expression for discriminating AML patients from controls. (D...
Kaplan-Meier curves for overall and event-free survival of patients with and without mutation and/or...
Kaplan-Meier curves for overall and event-free survival of the TCGA AML patients by (a) DNMT3A mutat...
Kaplan-Meier curves for overall and event-free survival of patients stratified by the status of m6A ...
A) Molecular analysis of CBFA2T3-GLIS2 fusion gene. 1.M07e, 2.WSU-AML, 3.KASUMI1, 4.NOMO1, 5.OCI-AML...
Figure S1: Title of data: Influences of TET2 mutation on prognosis in AML patients. Description of d...
Treatment resulted in a differential expression of 941 genes ( pâ <â0.05). (PDF 256 kb
Table S1. Patient’s characteristic of gene expression cohort. Table S2. Patient’s characteristic ex ...
The correlation of Rheb1 expression level with AML prognosis. (A) Kaplan-Meier event-free survival c...
Table S5. List of genes that were hypomethylated after CX-4945 incubation (FC<0.25) compared to cont...
Table S6. List of genes that were hypomethylated after combined CX-4945 and DEC incubation (FC<0.25)...
Additional file 2: Figure S2. KaplanâMeier survival analysis for overall survival (OS) using diffe...
DNMT3A expression, mutational status in leukemia strains and expression level of DNMT3A in various c...
Figure S6. WT1 mutations in the AML but not MDS samples of the patient. (DOCX 1483 kb
Figure S1. Mutation patterns of the identified 32 MDGs across 20 TCGA tumor types. Each row represen...
Figure S1. ROC curve analysis using H19 expression for discriminating AML patients from controls. (D...
Kaplan-Meier curves for overall and event-free survival of patients with and without mutation and/or...
Kaplan-Meier curves for overall and event-free survival of the TCGA AML patients by (a) DNMT3A mutat...
Kaplan-Meier curves for overall and event-free survival of patients stratified by the status of m6A ...
A) Molecular analysis of CBFA2T3-GLIS2 fusion gene. 1.M07e, 2.WSU-AML, 3.KASUMI1, 4.NOMO1, 5.OCI-AML...
Figure S1: Title of data: Influences of TET2 mutation on prognosis in AML patients. Description of d...
Treatment resulted in a differential expression of 941 genes ( pâ <â0.05). (PDF 256 kb
Table S1. Patient’s characteristic of gene expression cohort. Table S2. Patient’s characteristic ex ...
The correlation of Rheb1 expression level with AML prognosis. (A) Kaplan-Meier event-free survival c...
Table S5. List of genes that were hypomethylated after CX-4945 incubation (FC<0.25) compared to cont...
Table S6. List of genes that were hypomethylated after combined CX-4945 and DEC incubation (FC<0.25)...
Additional file 2: Figure S2. KaplanâMeier survival analysis for overall survival (OS) using diffe...
DNMT3A expression, mutational status in leukemia strains and expression level of DNMT3A in various c...
Figure S6. WT1 mutations in the AML but not MDS samples of the patient. (DOCX 1483 kb
Figure S1. Mutation patterns of the identified 32 MDGs across 20 TCGA tumor types. Each row represen...
Figure S1. ROC curve analysis using H19 expression for discriminating AML patients from controls. (D...